nodes	percent_of_prediction	percent_of_DWPC	metapath
Acetazolamide—CYP3A4—bone cancer	0.869	1	CbGaD
Acetazolamide—AQP1—cartilage tissue—bone cancer	0.00743	0.277	CbGeAlD
Acetazolamide—Hepatic insufficiency—Methotrexate—bone cancer	0.00634	0.0646	CcSEcCtD
Acetazolamide—Methazolamide—CYP3A4—bone cancer	0.00622	1	CrCbGaD
Acetazolamide—Reaction gastrointestinal—Methotrexate—bone cancer	0.00294	0.0299	CcSEcCtD
Acetazolamide—CA2—periosteum—bone cancer	0.00283	0.105	CbGeAlD
Acetazolamide—Appetite absent—Methotrexate—bone cancer	0.00197	0.0201	CcSEcCtD
Acetazolamide—AQP1—connective tissue—bone cancer	0.00185	0.0689	CbGeAlD
Acetazolamide—Body temperature increased—Carboplatin—bone cancer	0.00172	0.0175	CcSEcCtD
Acetazolamide—Polyuria—Cisplatin—bone cancer	0.00148	0.015	CcSEcCtD
Acetazolamide—CA3—connective tissue—bone cancer	0.00136	0.0505	CbGeAlD
Acetazolamide—Anaphylactoid reaction—Cisplatin—bone cancer	0.00134	0.0136	CcSEcCtD
Acetazolamide—Hyponatraemia—Cisplatin—bone cancer	0.0013	0.0133	CcSEcCtD
Acetazolamide—AQP1—tendon—bone cancer	0.00127	0.0474	CbGeAlD
Acetazolamide—Irritability—Cisplatin—bone cancer	0.00124	0.0126	CcSEcCtD
Acetazolamide—AQP1—bone marrow—bone cancer	0.00123	0.0459	CbGeAlD
Acetazolamide—AQP1—spinal cord—bone cancer	0.00122	0.0457	CbGeAlD
Acetazolamide—Hypokalaemia—Cisplatin—bone cancer	0.00118	0.012	CcSEcCtD
Acetazolamide—Glycosuria—Epirubicin—bone cancer	0.00113	0.0115	CcSEcCtD
Acetazolamide—Injection site pain—Epirubicin—bone cancer	0.00112	0.0114	CcSEcCtD
Acetazolamide—Blood disorder—Epirubicin—bone cancer	0.0011	0.0112	CcSEcCtD
Acetazolamide—Glycosuria—Doxorubicin—bone cancer	0.00105	0.0107	CcSEcCtD
Acetazolamide—Jaundice cholestatic—Epirubicin—bone cancer	0.00104	0.0106	CcSEcCtD
Acetazolamide—Injection site pain—Doxorubicin—bone cancer	0.00104	0.0106	CcSEcCtD
Acetazolamide—Blood disorder—Doxorubicin—bone cancer	0.00102	0.0104	CcSEcCtD
Acetazolamide—Jaundice cholestatic—Doxorubicin—bone cancer	0.000966	0.00984	CcSEcCtD
Acetazolamide—CA12—connective tissue—bone cancer	0.00096	0.0358	CbGeAlD
Acetazolamide—Melaena—Methotrexate—bone cancer	0.000958	0.00975	CcSEcCtD
Acetazolamide—Hepatobiliary disease—Cisplatin—bone cancer	0.000945	0.00963	CcSEcCtD
Acetazolamide—CA3—tendon—bone cancer	0.000931	0.0347	CbGeAlD
Acetazolamide—Aplastic anaemia—Methotrexate—bone cancer	0.000921	0.00938	CcSEcCtD
Acetazolamide—CA3—bone marrow—bone cancer	0.000902	0.0336	CbGeAlD
Acetazolamide—Melaena—Epirubicin—bone cancer	0.000896	0.00913	CcSEcCtD
Acetazolamide—CA9—tendon—bone cancer	0.000892	0.0333	CbGeAlD
Acetazolamide—Urine output increased—Methotrexate—bone cancer	0.000887	0.00903	CcSEcCtD
Acetazolamide—Aplastic anaemia—Epirubicin—bone cancer	0.000862	0.00877	CcSEcCtD
Acetazolamide—CA14—tendon—bone cancer	0.000846	0.0315	CbGeAlD
Acetazolamide—Tinnitus—Cisplatin—bone cancer	0.000837	0.00852	CcSEcCtD
Acetazolamide—Flushing—Cisplatin—bone cancer	0.000833	0.00848	CcSEcCtD
Acetazolamide—Melaena—Doxorubicin—bone cancer	0.000829	0.00845	CcSEcCtD
Acetazolamide—CA14—spinal cord—bone cancer	0.000816	0.0304	CbGeAlD
Acetazolamide—Polyuria—Methotrexate—bone cancer	0.000811	0.00826	CcSEcCtD
Acetazolamide—Photosensitivity—Methotrexate—bone cancer	0.000811	0.00826	CcSEcCtD
Acetazolamide—Aplastic anaemia—Doxorubicin—bone cancer	0.000797	0.00812	CcSEcCtD
Acetazolamide—Hepatic failure—Methotrexate—bone cancer	0.000792	0.00807	CcSEcCtD
Acetazolamide—Hepatic function abnormal—Epirubicin—bone cancer	0.000762	0.00776	CcSEcCtD
Acetazolamide—Photosensitivity—Epirubicin—bone cancer	0.000759	0.00773	CcSEcCtD
Acetazolamide—Hepatic failure—Epirubicin—bone cancer	0.000741	0.00755	CcSEcCtD
Acetazolamide—Anaphylactoid reaction—Methotrexate—bone cancer	0.000735	0.00749	CcSEcCtD
Acetazolamide—Ill-defined disorder—Cisplatin—bone cancer	0.000725	0.00738	CcSEcCtD
Acetazolamide—Hepatic function abnormal—Doxorubicin—bone cancer	0.000705	0.00718	CcSEcCtD
Acetazolamide—Malaise—Cisplatin—bone cancer	0.000704	0.00717	CcSEcCtD
Acetazolamide—Photosensitivity—Doxorubicin—bone cancer	0.000702	0.00715	CcSEcCtD
Acetazolamide—Leukopenia—Cisplatin—bone cancer	0.000699	0.00712	CcSEcCtD
Acetazolamide—Anaphylactoid reaction—Epirubicin—bone cancer	0.000688	0.00701	CcSEcCtD
Acetazolamide—Hepatic failure—Doxorubicin—bone cancer	0.000686	0.00698	CcSEcCtD
Acetazolamide—Hypoglycaemia—Epirubicin—bone cancer	0.000683	0.00695	CcSEcCtD
Acetazolamide—Irritability—Methotrexate—bone cancer	0.000679	0.00692	CcSEcCtD
Acetazolamide—Convulsion—Cisplatin—bone cancer	0.000677	0.00689	CcSEcCtD
Acetazolamide—Ataxia—Methotrexate—bone cancer	0.000669	0.00682	CcSEcCtD
Acetazolamide—Hyponatraemia—Epirubicin—bone cancer	0.000669	0.00681	CcSEcCtD
Acetazolamide—Discomfort—Cisplatin—bone cancer	0.000657	0.00669	CcSEcCtD
Acetazolamide—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000641	0.00653	CcSEcCtD
Acetazolamide—Anaphylactic shock—Cisplatin—bone cancer	0.000638	0.00649	CcSEcCtD
Acetazolamide—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000637	0.00649	CcSEcCtD
Acetazolamide—Hypoglycaemia—Doxorubicin—bone cancer	0.000632	0.00643	CcSEcCtD
Acetazolamide—Ataxia—Epirubicin—bone cancer	0.000626	0.00638	CcSEcCtD
Acetazolamide—Thrombocytopenia—Cisplatin—bone cancer	0.000624	0.00636	CcSEcCtD
Acetazolamide—Hyponatraemia—Doxorubicin—bone cancer	0.000619	0.0063	CcSEcCtD
Acetazolamide—Hypokalaemia—Epirubicin—bone cancer	0.000606	0.00617	CcSEcCtD
Acetazolamide—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.0006	0.00611	CcSEcCtD
Acetazolamide—CA5B—tendon—bone cancer	0.000592	0.0221	CbGeAlD
Acetazolamide—Ataxia—Doxorubicin—bone cancer	0.00058	0.0059	CcSEcCtD
Acetazolamide—Paraesthesia—Cisplatin—bone cancer	0.000572	0.00583	CcSEcCtD
Acetazolamide—Photosensitivity reaction—Methotrexate—bone cancer	0.000562	0.00572	CcSEcCtD
Acetazolamide—Hypokalaemia—Doxorubicin—bone cancer	0.000561	0.00571	CcSEcCtD
Acetazolamide—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000555	0.00565	CcSEcCtD
Acetazolamide—Decreased appetite—Cisplatin—bone cancer	0.000554	0.00564	CcSEcCtD
Acetazolamide—Gastrointestinal disorder—Cisplatin—bone cancer	0.00055	0.00561	CcSEcCtD
Acetazolamide—Drowsiness—Methotrexate—bone cancer	0.000549	0.00559	CcSEcCtD
Acetazolamide—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000544	0.00554	CcSEcCtD
Acetazolamide—Photosensitivity reaction—Epirubicin—bone cancer	0.000526	0.00535	CcSEcCtD
Acetazolamide—Feeling abnormal—Cisplatin—bone cancer	0.000525	0.00535	CcSEcCtD
Acetazolamide—Haematuria—Methotrexate—bone cancer	0.000523	0.00533	CcSEcCtD
Acetazolamide—Hepatobiliary disease—Methotrexate—bone cancer	0.000519	0.00528	CcSEcCtD
Acetazolamide—Drowsiness—Epirubicin—bone cancer	0.000513	0.00523	CcSEcCtD
Acetazolamide—Agranulocytosis—Methotrexate—bone cancer	0.000512	0.00521	CcSEcCtD
Acetazolamide—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000509	0.00518	CcSEcCtD
Acetazolamide—CA1—bone marrow—bone cancer	0.000506	0.0189	CbGeAlD
Acetazolamide—Body temperature increased—Cisplatin—bone cancer	0.000504	0.00513	CcSEcCtD
Acetazolamide—CA1—spinal cord—bone cancer	0.000504	0.0188	CbGeAlD
Acetazolamide—CA2—connective tissue—bone cancer	0.000493	0.0184	CbGeAlD
Acetazolamide—Haematuria—Epirubicin—bone cancer	0.000489	0.00498	CcSEcCtD
Acetazolamide—Photosensitivity reaction—Doxorubicin—bone cancer	0.000486	0.00495	CcSEcCtD
Acetazolamide—Hepatobiliary disease—Epirubicin—bone cancer	0.000485	0.00494	CcSEcCtD
Acetazolamide—Agranulocytosis—Epirubicin—bone cancer	0.000479	0.00488	CcSEcCtD
Acetazolamide—Drowsiness—Doxorubicin—bone cancer	0.000475	0.00484	CcSEcCtD
Acetazolamide—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000471	0.0048	CcSEcCtD
Acetazolamide—Erythema multiforme—Methotrexate—bone cancer	0.000466	0.00474	CcSEcCtD
Acetazolamide—Tinnitus—Methotrexate—bone cancer	0.000459	0.00468	CcSEcCtD
Acetazolamide—Hypoaesthesia—Epirubicin—bone cancer	0.000459	0.00467	CcSEcCtD
Acetazolamide—Asthenia—Cisplatin—bone cancer	0.000457	0.00466	CcSEcCtD
Acetazolamide—Haematuria—Doxorubicin—bone cancer	0.000453	0.00461	CcSEcCtD
Acetazolamide—Hepatobiliary disease—Doxorubicin—bone cancer	0.000449	0.00457	CcSEcCtD
Acetazolamide—Agranulocytosis—Doxorubicin—bone cancer	0.000443	0.00451	CcSEcCtD
Acetazolamide—Diarrhoea—Cisplatin—bone cancer	0.000436	0.00444	CcSEcCtD
Acetazolamide—Erythema multiforme—Epirubicin—bone cancer	0.000436	0.00444	CcSEcCtD
Acetazolamide—Tinnitus—Epirubicin—bone cancer	0.00043	0.00438	CcSEcCtD
Acetazolamide—Flushing—Epirubicin—bone cancer	0.000428	0.00436	CcSEcCtD
Acetazolamide—Hypoaesthesia—Doxorubicin—bone cancer	0.000424	0.00432	CcSEcCtD
Acetazolamide—Dysgeusia—Methotrexate—bone cancer	0.00042	0.00427	CcSEcCtD
Acetazolamide—CA4—tendon—bone cancer	0.000408	0.0152	CbGeAlD
Acetazolamide—Vomiting—Cisplatin—bone cancer	0.000405	0.00413	CcSEcCtD
Acetazolamide—Erythema multiforme—Doxorubicin—bone cancer	0.000403	0.00411	CcSEcCtD
Acetazolamide—Ill-defined disorder—Methotrexate—bone cancer	0.000398	0.00405	CcSEcCtD
Acetazolamide—Tinnitus—Doxorubicin—bone cancer	0.000398	0.00405	CcSEcCtD
Acetazolamide—Flushing—Doxorubicin—bone cancer	0.000396	0.00403	CcSEcCtD
Acetazolamide—CA4—bone marrow—bone cancer	0.000396	0.0148	CbGeAlD
Acetazolamide—CA4—spinal cord—bone cancer	0.000394	0.0147	CbGeAlD
Acetazolamide—Dysgeusia—Epirubicin—bone cancer	0.000393	0.004	CcSEcCtD
Acetazolamide—Malaise—Methotrexate—bone cancer	0.000387	0.00394	CcSEcCtD
Acetazolamide—Leukopenia—Methotrexate—bone cancer	0.000384	0.00391	CcSEcCtD
Acetazolamide—Nausea—Cisplatin—bone cancer	0.000379	0.00386	CcSEcCtD
Acetazolamide—Ill-defined disorder—Epirubicin—bone cancer	0.000372	0.00379	CcSEcCtD
Acetazolamide—Convulsion—Methotrexate—bone cancer	0.000371	0.00378	CcSEcCtD
Acetazolamide—Agitation—Epirubicin—bone cancer	0.000369	0.00375	CcSEcCtD
Acetazolamide—Dysgeusia—Doxorubicin—bone cancer	0.000363	0.0037	CcSEcCtD
Acetazolamide—Malaise—Epirubicin—bone cancer	0.000362	0.00368	CcSEcCtD
Acetazolamide—Discomfort—Methotrexate—bone cancer	0.000361	0.00367	CcSEcCtD
Acetazolamide—Leukopenia—Epirubicin—bone cancer	0.000359	0.00366	CcSEcCtD
Acetazolamide—Confusional state—Methotrexate—bone cancer	0.000353	0.00359	CcSEcCtD
Acetazolamide—Anaphylactic shock—Methotrexate—bone cancer	0.00035	0.00356	CcSEcCtD
Acetazolamide—Convulsion—Epirubicin—bone cancer	0.000348	0.00354	CcSEcCtD
Acetazolamide—Ill-defined disorder—Doxorubicin—bone cancer	0.000344	0.00351	CcSEcCtD
Acetazolamide—Thrombocytopenia—Methotrexate—bone cancer	0.000343	0.00349	CcSEcCtD
Acetazolamide—Agitation—Doxorubicin—bone cancer	0.000341	0.00347	CcSEcCtD
Acetazolamide—CA2—tendon—bone cancer	0.000339	0.0126	CbGeAlD
Acetazolamide—Discomfort—Epirubicin—bone cancer	0.000337	0.00344	CcSEcCtD
Acetazolamide—Malaise—Doxorubicin—bone cancer	0.000335	0.00341	CcSEcCtD
Acetazolamide—Leukopenia—Doxorubicin—bone cancer	0.000332	0.00338	CcSEcCtD
Acetazolamide—Confusional state—Epirubicin—bone cancer	0.00033	0.00336	CcSEcCtD
Acetazolamide—CA2—bone marrow—bone cancer	0.000328	0.0122	CbGeAlD
Acetazolamide—Anaphylactic shock—Epirubicin—bone cancer	0.000327	0.00333	CcSEcCtD
Acetazolamide—CA2—spinal cord—bone cancer	0.000327	0.0122	CbGeAlD
Acetazolamide—Shock—Epirubicin—bone cancer	0.000322	0.00328	CcSEcCtD
Acetazolamide—Convulsion—Doxorubicin—bone cancer	0.000322	0.00328	CcSEcCtD
Acetazolamide—Thrombocytopenia—Epirubicin—bone cancer	0.000321	0.00326	CcSEcCtD
Acetazolamide—Paraesthesia—Methotrexate—bone cancer	0.000314	0.0032	CcSEcCtD
Acetazolamide—Discomfort—Doxorubicin—bone cancer	0.000312	0.00318	CcSEcCtD
Acetazolamide—Somnolence—Methotrexate—bone cancer	0.000311	0.00317	CcSEcCtD
Acetazolamide—Dyspepsia—Methotrexate—bone cancer	0.000308	0.00314	CcSEcCtD
Acetazolamide—Confusional state—Doxorubicin—bone cancer	0.000305	0.00311	CcSEcCtD
Acetazolamide—Decreased appetite—Methotrexate—bone cancer	0.000304	0.0031	CcSEcCtD
Acetazolamide—Anaphylactic shock—Doxorubicin—bone cancer	0.000303	0.00308	CcSEcCtD
Acetazolamide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000302	0.00308	CcSEcCtD
Acetazolamide—Fatigue—Methotrexate—bone cancer	0.000302	0.00307	CcSEcCtD
Acetazolamide—Shock—Doxorubicin—bone cancer	0.000298	0.00304	CcSEcCtD
Acetazolamide—Thrombocytopenia—Doxorubicin—bone cancer	0.000297	0.00302	CcSEcCtD
Acetazolamide—Paraesthesia—Epirubicin—bone cancer	0.000294	0.00299	CcSEcCtD
Acetazolamide—Somnolence—Epirubicin—bone cancer	0.000291	0.00296	CcSEcCtD
Acetazolamide—Feeling abnormal—Methotrexate—bone cancer	0.000288	0.00294	CcSEcCtD
Acetazolamide—Dyspepsia—Epirubicin—bone cancer	0.000288	0.00293	CcSEcCtD
Acetazolamide—Decreased appetite—Epirubicin—bone cancer	0.000285	0.0029	CcSEcCtD
Acetazolamide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000283	0.00288	CcSEcCtD
Acetazolamide—Fatigue—Epirubicin—bone cancer	0.000282	0.00287	CcSEcCtD
Acetazolamide—Urticaria—Methotrexate—bone cancer	0.000278	0.00283	CcSEcCtD
Acetazolamide—Body temperature increased—Methotrexate—bone cancer	0.000277	0.00282	CcSEcCtD
Acetazolamide—Paraesthesia—Doxorubicin—bone cancer	0.000272	0.00277	CcSEcCtD
Acetazolamide—Feeling abnormal—Epirubicin—bone cancer	0.00027	0.00275	CcSEcCtD
Acetazolamide—Somnolence—Doxorubicin—bone cancer	0.000269	0.00274	CcSEcCtD
Acetazolamide—Dyspepsia—Doxorubicin—bone cancer	0.000267	0.00272	CcSEcCtD
Acetazolamide—Decreased appetite—Doxorubicin—bone cancer	0.000263	0.00268	CcSEcCtD
Acetazolamide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000262	0.00266	CcSEcCtD
Acetazolamide—Fatigue—Doxorubicin—bone cancer	0.000261	0.00266	CcSEcCtD
Acetazolamide—Urticaria—Epirubicin—bone cancer	0.00026	0.00265	CcSEcCtD
Acetazolamide—Body temperature increased—Epirubicin—bone cancer	0.000259	0.00264	CcSEcCtD
Acetazolamide—Asthenia—Methotrexate—bone cancer	0.000251	0.00256	CcSEcCtD
Acetazolamide—Feeling abnormal—Doxorubicin—bone cancer	0.00025	0.00254	CcSEcCtD
Acetazolamide—Urticaria—Doxorubicin—bone cancer	0.000241	0.00245	CcSEcCtD
Acetazolamide—Body temperature increased—Doxorubicin—bone cancer	0.000239	0.00244	CcSEcCtD
Acetazolamide—Diarrhoea—Methotrexate—bone cancer	0.000239	0.00244	CcSEcCtD
Acetazolamide—Asthenia—Epirubicin—bone cancer	0.000235	0.00239	CcSEcCtD
Acetazolamide—Dizziness—Methotrexate—bone cancer	0.000231	0.00236	CcSEcCtD
Acetazolamide—Diarrhoea—Epirubicin—bone cancer	0.000224	0.00228	CcSEcCtD
Acetazolamide—Vomiting—Methotrexate—bone cancer	0.000222	0.00227	CcSEcCtD
Acetazolamide—Headache—Methotrexate—bone cancer	0.000219	0.00223	CcSEcCtD
Acetazolamide—Asthenia—Doxorubicin—bone cancer	0.000217	0.00221	CcSEcCtD
Acetazolamide—Dizziness—Epirubicin—bone cancer	0.000217	0.0022	CcSEcCtD
Acetazolamide—Vomiting—Epirubicin—bone cancer	0.000208	0.00212	CcSEcCtD
Acetazolamide—Nausea—Methotrexate—bone cancer	0.000208	0.00212	CcSEcCtD
Acetazolamide—Diarrhoea—Doxorubicin—bone cancer	0.000207	0.00211	CcSEcCtD
Acetazolamide—Headache—Epirubicin—bone cancer	0.000205	0.00209	CcSEcCtD
Acetazolamide—Dizziness—Doxorubicin—bone cancer	0.0002	0.00204	CcSEcCtD
Acetazolamide—Nausea—Epirubicin—bone cancer	0.000194	0.00198	CcSEcCtD
Acetazolamide—Vomiting—Doxorubicin—bone cancer	0.000193	0.00196	CcSEcCtD
Acetazolamide—Headache—Doxorubicin—bone cancer	0.00019	0.00193	CcSEcCtD
Acetazolamide—Nausea—Doxorubicin—bone cancer	0.00018	0.00183	CcSEcCtD
